tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schnitzler M Diabetes mellitus after kidney transplantation in the United States. 2003 Am. J. Transplant. pmid:14510709
Frassetto LA et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. 2007 Am. J. Transplant. pmid:17949460
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
English RF et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. 2002 Am. J. Transplant. pmid:12243498
de Fontbrune FS et al. Veno-occlusive disease of the liver after lung transplantation. 2007 Am. J. Transplant. pmid:17697264
Abdelmalek MF et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 2012 Am. J. Transplant. pmid:22233522
Gupta G et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. 2015 Am. J. Transplant. pmid:25988397
Ekberg H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. 2009 Am. J. Transplant. pmid:19563339
Suszynski TM et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. 2013 Am. J. Transplant. pmid:23432755
Damon C et al. Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. 2017 Am. J. Transplant. pmid:27597269
Shuker N et al. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. 2016 Am. J. Transplant. pmid:26714287
Flechner SM et al. Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. 2010 Am. J. Transplant. pmid:20883540
Benítez CE et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. 2010 Am. J. Transplant. pmid:20883560
Böger CA et al. Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. 2006 Am. J. Transplant. pmid:16889550
Tan HP et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. 2006 Am. J. Transplant. pmid:16889606
Arnold R et al. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. 2013 Am. J. Transplant. pmid:23841745
Hirsch HH et al. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. 2016 Am. J. Transplant. pmid:26639422
Pescovitz MD et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. 2009 Am. J. Transplant. pmid:19663892
Bohl DL et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. 2005 Am. J. Transplant. pmid:16095500
Neuberger JM et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. 2009 Am. J. Transplant. pmid:19120077
Tan HP et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. 2009 Am. J. Transplant. pmid:19120078
Ashman N et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. 2009 Am. J. Transplant. pmid:19120084
Vongwiwatana A et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. 2004 Am. J. Transplant. pmid:14678043
Bressollette-Bodin C et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. 2005 Am. J. Transplant. pmid:15996241
De Simone P et al. Everolimus with reduced tacrolimus in liver transplantation. 2013 Am. J. Transplant. pmid:23601137
Awadalla Y et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. 2004 Am. J. Transplant. pmid:15367226
Luther P and Baldwin D Pioglitazone in the management of diabetes mellitus after transplantation. 2004 Am. J. Transplant. pmid:15575920
Cherukuri A et al. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. 2012 Am. J. Transplant. pmid:22390816
Dahm F et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. 2004 Am. J. Transplant. pmid:15575921
Pascher A et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. 2015 Am. J. Transplant. pmid:25677074
Chen G et al. A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. 2006 Am. J. Transplant. pmid:16539628
Okabayashi T et al. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. 2011 Am. J. Transplant. pmid:21883903
Zheng H et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. 2003 Am. J. Transplant. pmid:12694072
Montgomery SP et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 2002 Am. J. Transplant. pmid:12118862
Ahsan N et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. 2002 Am. J. Transplant. pmid:12118902
van Hooff JP et al. Glucose metabolic disorder after transplantation. 2007 Am. J. Transplant. pmid:17511670
Silva HT et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. 2007 Am. J. Transplant. pmid:17217442
Heffron TG et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. 2007 Am. J. Transplant. pmid:17511684
Moench C et al. Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. 2007 Am. J. Transplant. pmid:17511685
Tedesco-Silva H et al. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. 2015 Am. J. Transplant. pmid:25988935
Pech T et al. Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. 2012 Am. J. Transplant. pmid:22974463
Gallon L et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. 2006 Am. J. Transplant. pmid:16827862
Grenda R et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. 2006 Am. J. Transplant. pmid:16827869
Teuteberg JJ et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. 2010 Am. J. Transplant. pmid:19889126
Gaston RS et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. 2009 Am. J. Transplant. pmid:19459794
Turgut F and Akcay A Renal function estimation in cirrhosis. 2009 Am. J. Transplant. pmid:19519814
Irish WD et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 2011 Am. J. Transplant. pmid:21564522
Friman S et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. 2011 Am. J. Transplant. pmid:21564523
Brennan DC et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. 2005 Am. J. Transplant. pmid:15707414
Rogers J et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. 2003 Am. J. Transplant. pmid:14510702